Cantor Fitzgerald analyst Kristen Kluska raised the firm’s price target on Taysha Gene Therapies to $7 from $2 and keeps an Overweight rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TSHA:
- Why Taysha Gene Therapies (NASDAQ:TSHA) Doubled Its Value Today
- Taysha Gene Therapies expects cash to fund operations into 3Q25
- Taysha Gene Therapies reports Q2 EPS (38c), consensus (31c)
- Taysha Gene Therapies reports initial data from REVEAL Phase 1/2 trial
- Taysha Gene Therapies announces $150M private placement financing